THE FIFTH INTERNATIONAL CONGRESS OF CYTOLOGY

MIAMI BEACH, FLORIDA, U.S.A.
(Americana Hotel)
29 May–1 June 1974

Sponsored by the International Academy of Cytology, the American Society of Cytology and co-sponsored by the Argentinian, Australian, Austrian, Belgian, Brazilian, British, Canadian, Czechoslovakian, Dutch, Finnish, French, German, Indian, Israeli, Italian, Japanese, Latin-American, Mexican, New Zealand, Norwegian, South-African, Spanish, Swedish and Swiss National Societies of Cytology.

Scientific Programme: The Scientific Programme will consist of Congress Lectures by invited speakers, a Special Slide Seminar, Teaching Seminars, Scientific Exhibits, Poffered Papers in various fields of Cytology and various Panels.


Panels:
1. New Cytologic Techniques, Chairman, Dr B. N. Naylor (U.S.A.).
2. Actualities in Cytogenetics, Chairman, Dr G. F. Bahr (U.S.A.).
3. Role of the Computer in Cytology, Chairman, Dr G. L. Wied (U.S.A.).
4. New Aspects of Aspiration Cytology, Chairman, Dr. J. Zajicek (Sweden).
7. Vaginal Microbiology, Chairman, Dr J. Zidovsky (Czechoslovakia).

If wishing to participate or attend, please ask for the Congress Booklet from: The Secretary General, 5th International Congress of Cytology, 1050, Chemin Ste-Foy, Quebec, P.Q., Canada, G1S 4L8.
Depostat
designed to reduce the risk of metastatic spread
in endometrial carcinoma

Curettings showing
a moderately differentiated adenocarcinoma.

After pre-operative treatment with Depostat.
Hysterectomy specimen shows better differentiation of the tumour.
Well-formed acini with good secretory activity are evident.
The mitotic rate is greatly reduced.

Pre-operatively Depostat
exerts a strong anti-mitotic effect on endometrial tissue.
reduces the friability of the tumour.
may prevent tumour emboli from becoming established metastases.

Post-operatively Depostat
inhibits through its strong anti-mitotic properties any
metastatic spread which has already occurred.
can be used synergistically with cytotoxic agents.
may improve the quality of life of those patients with inoperable conditions.

Depostat
does not impair adrenal function, and side-effects are rare.

Depostat
another step forward in the treatment of cancer

DEPOSTAT®

Presentation 17-alpha-hydroxy-19-
norpregesterone caproate (Gestronol
Hexanoate BP, Gestonorone
Caproate USP) in oily solution for
intramuscular administration.
Ampoules containing 200 mg in 2 ml.
Endometrial carcinoma. Depostat is a
depot progestagen, in a
concentrated injectable non-aqueous
solution, and is 25 times more potent
than its parent substance
pregesterone. In the female the
action of Depostat is concentrated on
the endometrium. This action is
direct and does not involve
suppression via the pituitary.
Depostat has been shown to cause
temporary regression or arrest of
tumour growth and soft-tissue
metastases in endometrial carcinoma,
with a pronounced antimotic effect.

Dosage and administration
Endometrial carcinoma, before
hysterectomy and for advanced
disease. A well-tolerated adjunct to
other therapy. To inhibit metastatic
spread, before and after operation.
200–400 mg intramuscularly every
five days, starting immediately
following diagnosis and continuing
for a minimum of 12 weeks.
For treating existing metastases:
200–400 mg intramuscularly every
five days. If the metastases are
hormone-responsive, improvement
will be observed after 6–12 weeks of
therapy. Treatment should then be
continued as long as it appears
beneficial.
The standard dosage of Depostat is
200 mg weekly by intramuscular
injection, but in view of its excellent
tolerance, this dosage can confidently
be increased. In trials, 300 mg and
400 mg weekly have been used.

Contra-indications, warnings, etc
Rarely, local reactions may occur at
the site of injection. Depostat should
not be given during pregnancy.
Exacerbation of bronchial asthma,
epilepsy and migraine may
sometimes occur.

Tolerance: Tolerance of Depostat is
excellent. In patients with chronic
liver damage it is advisable to check
liver function at intervals during
long-term treatment or repeated
courses of Depostat. Transient
moderate rises in bromsulphthalein
retention and serum transaminases
have occasionally been observed but
have always proved harmless.

Pharmaceutical precautions Storage.
Store in cool, dry conditions away
from strong sunlight. Shelf-life five
years.

Legal category S4B.

Package quantities 5 ampoules of 2 ml.

Further information Nil.

Product licence number 0053/0018.
© SCL November 1973 U.K. 10805

Schering Chemicals Limited,
Pharmaceutical Division,
Burgess Hill, Sussex. RH15 8NE.